VALSARTAN

VALSARTAN
(val-sar'tan)
Diovan
Classifications: angiotensin ii receptor antagonist; antihypertensive;
Therapeutic: antihypertensive
; angiotensin ii receptor antagonist
Prototype: Losartan
Pregnancy Category: C first trimester; D second and third trimester

Availability

40 mg, 80 mg, 160 mg capsules

Action

An angiotensin II receptor (type AT1) antagonist that blocks the angiotensin converting enzyme (ACE); it inhibits the binding of angiotensin II to the AT1 receptors found in many tissues (e.g., vascular smooth muscle, adrenal glands). Angiotensin II is a potent vasoconstrictor and primary vasoactive hormone of the renin–angiotensin–aldosterone system.

Therapeutic Effect

Blocking the angiotensin II receptor results in vasodilation and blocking of the aldosterone-secreting effects of angiotensin II, thus resulting in an antihypertensive effect.

Uses

Treatment of hypertension, heart failure.

Contraindications

Hypersensitivity to valsartan or losartan; pregnancy [(category C) first trimester, (category D) second and third trimesters], lactation; severe heart failure with compromised renal function.

Cautious Use

Severe renal or hepatic impairment; renal artery stenosis; hypovolemia; congestive heart failure. Safety and efficacy in children <18 y are not established.

Route & Dosage

Hypertension
Adult: PO 80 mg q.d. (max: 320 mg q.d.)

Heart Failure
Adult: PO Start with 40 mg b.i.d. and titrate up to 160 mg b.i.d.


Hemodialysis: Adjustment not needed

Administration

Oral
  • Give on an empty stomach.
  • Correct volume depletion prior to initiation of therapy to prevent hypotension.
  • Reduce dosage with severe hepatic or renal impairment.
  • Note: Daily dose may be titrated up to 320 mg.
  • Store at 15°–30° C (59°–86° F).

Adverse Effects (≥1%)

Body as a Whole: Arthralgia. CNS: Headache, dizziness. GI: Diarrhea, nausea. Respiratory: Cough, sinusitis. Metabolic: Hyperkalemia.

Pharmacokinetics

Absorption: Rapidly from GI tract, 25% bioavailability. Onset: Blood pressure decreased in 2 wk. Peak: Plasma levels, 2–4 h; blood pressure effect 4 wk. Distribution: 99% protein bound. Metabolism: In the liver. Elimination: Primarily in feces. Half-Life: 6 h.

Nursing Implications

Assessment & Drug Effects

  • Monitor BP periodically; take trough readings, just prior to the next scheduled dose, when possible.
  • Lab tests: Monitor liver function tests, BUN and creatinine, serum potassium, and CBC with differential, periodically.

Patient & Family Education

  • Inform physician immediately if you become pregnant.
  • Note: Maximum pressure lowering effect is usually evident between 2 and 4 wk after initiation of therapy.
  • Notify physician of episodes of dizziness, especially those that occur when making position changes.

Common adverse effects in italic, life-threatening effects underlined; generic names in bold; classifications in SMALL CAPS; Canadian drug name; Prototype drug

(181)
This site is intended for general information only. The information provided on this site does not constitute medical advice and should not be relied upon. You should not act or refrain from acting on any legal or medical matter based on the content of this site.
© 2006-2025 medpill.info Last Updated On: 05/19/2025 (0)
×
Wait 20 seconds...!!!